We describe the case of a woman who had two perioperative hypertensive crises that may have been due to her use of phentermine, a little-known sympathomimetic anti-obesity medication. The currently available anti-obesity medications are discussed: phentermine, diethylpropion, and sibutramine; all of which are sympathomimetics possessing noradrenaline and serotonin reuptake inhibitor activity. These medications should be discontinued one week preoperatively and have potential interactions with tramadol and antidepressants. The drug orlistat inhibits gastrointestinal lipase and may lead to fat soluble vitamin (A, D, E, and K) deficiency, so consideration should be given to checking coagulation status preoperatively.
Phentermine (Duromine™, 3M Pharmaceuticals)
is an older sympathomimetic anti-obesity medication that may produce side-effects relevant to the practice of anaesthesia. We describe a case illustrating these issues and discuss the relevant pharmacology of antiobesity medications.
CASE HISTORY
A 46-year-old woman was seen in the preadmission clinic, one week preoperatively, for scheduled laparotomy for resection of a uterine fibroid. She had a history of type II diabetes mellitus requiring insulin, hypertension and hypercholesterolemia. Her medications included insulin twice daily, ramipril nocte, atorvastatin nocte, and phentermine 40 mg mane. Her blood pressure at the preadmission clinic was 145/88 mmHg and her body mass index (BMI) was 32.7 kg/m 2 . Her ECG was normal. She described excellent exercise tolerance with no cardiac symptoms. She was asked to take her regular ramipril and atorvastatin the night before surgery and half her normal insulin dose on the day of surgery. She was also asked to cease her phentermine for two days: the day before and the morning of her surgery.
Prior to induction the patient was given intravenous midazolam 2.5 mg, followed by 1 mg. In the operating theatre her initial blood pressure reading was 175/90 mmHg. She was induced with propofol 150 mg, fentanyl 100 µg, and rocuronium 35 mg. After induction her blood pressure increased and over the next half hour continued to rise, peaking at 250/125 mmHg. Her heart rate rose from 80 to 90 beats per minute (bpm) to briefly peak at 120, but mostly remained below 100. During this period of time, various explanations were entertained for the hypertension and simultaneously, treatment was attempted. Potential awareness was treated with two boluses of propofol 50 mg, by checking sevoflurane end-tidal concentrations (increasing sevoflurane to 8%), and applying the BIS monitor (which read 5). Additional help was requested and the surgical team was alerted. By this time the most likely diagnosis was phaeochromocytoma, contraindicating beta-blockers because of the risk of severe elevation of blood pressure due to unopposed alpha sympathetic activity. Phentolamine 1 mg was given twice with good response, the blood pressure decreasing to 120/ 60 mmHg. An arterial line was inserted and the patient's systolic blood pressure again rose to 150 to 180 mmHg. It was decided to abandon the procedure because of the danger of intra-abdominal surgery in the presence of undiagnosed phaeochromocytoma, coupled with the surgical opinion that the operation was likely to be technically difficult. Neuromuscular block was reversed, the patient was extubated and taken to the recovery room where she remained haemodynamically stable for two hours, with her blood pressure in the range 140 to 160 mmHg systolic and 60 to 70 mmHg diastolic and a heart rate of 50 to 90 bpm.
In the high dependency unit an endocrinology consultation was requested. The endocrinologist thought her hypertension was due to the phentermine, but agreed that pheochromocytoma needed to be excluded. He also recommended baseline renal function, thyroid function, renin, cortisol, and aldosterone levels, to exclude other causes of hypertension. Following an overnight stay in the high dependency unit, she was discharged from the ward two days later after an unremarkable recovery, during which her blood pressure had been stable.
Her blood tests, including urinary catecholamines and vanillymandelic acid screen were normal. She was asked to see her endocrinologist and to then contact the gynaecologist to re-schedule her operation. As the endocrinologist believed the hypertension was due to phentermine, the patient was asked to cease this five days preoperatively on this occasion.
Four weeks later she returned for a total abdominal hysterectomy, having ceased her phentermine as instructed and continued ramipril preoperatively. At induction her blood pressure was 175/85 mmHg. An arterial line was not used. She received propofol 80 mg, alfentanil 2 mg, rocuronium 50 mg, and morphine intermittently to a total of 20 mg. Her blood pressure decreased after induction to 100/50 mmHg, then slowly rose, stabilizing at 175/80 mmHg. Her heart rate remained stable at 80 bpm. Surgery was uncomplicated, neuromuscular block was reversed, and she was taken to recovery and extubated quickly. Following extubation her blood pressure was 198/ 88 mmHg but increased to 227/90 mmHg. She complained of abdominal pain and was given intravenous hydralazine 5 mg and tramadol 100 mg. Her pain settled but hypertension persisted despite another 5 mg of hydralazine. Her systolic blood pressure remained above 200 mmHg, so a further 8 mg of hydralazine and metoprolol 5 mg were given. When her blood pressure decreased to 180/75 mmHg she was sent to the high dependency unit for close monitoring and a physician consultation.
The patient's blood pressure was stable overnight, ranging from 120 to 160 mmHg systolic with a pulse rate of 70 to 95 bpm. The physician recommended a renal artery duplex scan to exclude renal artery stenosis, but the scan was normal. Her blood pressure remained normal postoperatively and she was discharged home after three days. The patient's endocrinologist noted that she had had labile blood pressure at her visits, but never as high as during the perioperative periods and he expressed surprise that she remained on phentermine.
DISCUSSION
Intraoperative and postoperative uncontrolled hypertension in this patient may have been related to phentermine. Obesity is an increasing problem and the use of anti-obesity medications is likely to become increasingly prevalent. Some doctors advocate aggressive medical or surgical treatment of obesity to avoid its well-known medical consequences 1 . These medications may have implications during anaesthesia and their pharmacology deserves to be more widely known. Anti-obesity medications may not be mentioned by the patient at a pre-anaesthesia consultation due to embarrassment or a patient's belief that they are not clinically relevant.
Anti-obesity medications are categorized as centrally or peripherally acting. There are three centrally acting drugs and one peripherally acting available in Australia: phentermine (Duromine™), diethylpropion hydrochloride (Tenuate™, Aventis Pharma); sibutramine (Reductil™, Abbott) and orlistat (Xenical™, Roche).
Phentermine is a centrally acting sympathomimetic drug. It is structurally related to amphetamine, primarily increasing noradrenaline release and inhibiting reuptake, resulting in increased sympathetic nervous system activity 2 . It is a very weak inhibitor of monoamine oxidase, and although this is not believed to be of clinical significance 3 , the drug product information states that phentermine should not be prescribed with monoamine oxidase inhibitors. Phentermine is contraindicated for patients with moderate or severe hypertension and the product information suggests that patients with hypertension should be monitored in the first few days of treatment to ensure there is no loss of blood pressure control. Patients have required cessation of phentermine secondary to hypertension 4 . Phentermine may be associated with hypotension perioperatively due to catecholamine depletion and overdose may cause cardiac arrhythmias, hypertension, hypotension, tremor and panic states. It also weakly inhibits serotonin reuptake 3 , and administration with serotonin re-uptake inhibitors is not recommended. Serotonergic activity may explain phentermine's association with valvular heart disease when given with fenfluramine 5 , which releases and inhibits reuptake of serotonin much more strongly than phentermine 3 . The combination is associated with valvular heart disease that bears a strong resemblance to carcinoid syndrome 6 and this led to the withdrawal of fenfluramine from the market in the U.S.A. in 1997. Phentermine alone has not been associated with this complication, but with both fenfluramine and dexfenfluramine pulmonary hypertension has been described 7 .
We suggest that this patient's hypertensive episodes may have been related to her use of phentermine. Phentermine can cause or exacerbate hypertension and the preparation available in Australia is a sustained-release formulation with a half-life of approximately twenty-four hours (Product Information). This may account for the hypertension after the second operation, because phentermine had been stopped for the bare minimum of five elimination half-lives. We now advocate arterial blood pressure monitoring and the consideration of peripoperative beta-blockade and clonidine, to improve haemodynamic stability 8 . Tramadol should be avoided. Given this patient's labile blood pressure and episodic hypertension despite treatment, we consider that phentermine was not an appropriate anti-obesity medication for her.
Three other anti-obesity medications are available in Australia. Diethylpropion is another centrally acting sympathomimetic drug that acts by stimulating noradrenaline release and blocking its reuptake. Its half-life is four to six hours and it is given three times a day. It is has structural similarity to amphetamine and may be associated with similar side-effects to phentermine 9 .
Sibutramine is a centrally acting drug that inhibits reuptake of noradrenaline and serotonin, increasing sympathetic nervous system activity 2 , with potential increases in heart rate and blood pressure 9 . It is also contraindicated for patients on serotonin re-uptake inhibitors, tramadol and monoamine oxidase inhibitors, although it does not inhibit monoamine oxidase 3 . Its half-life is sixteen to eighteen hours 9 .
Orlistat is a gastrointestinal lipase inhibitor that impairs the absorption of dietary fat 1 . Its use requires adherence to a low fat diet or patients experience diarrhoea and steatorrhoea. Malabsorption of the fat-soluble vitamins A, D, E, and K is possible and prophylactic vitamin supplements are recommended. It seems unlikely that this medication would be of anaesthetic significance, except the theoretical possibility of vitamin K deficiency and coagulopathy.
We have described a case of severe hypertension that may have been related to the use of an antiobesity medication, although the patient may also have had extremely labile blood pressure unrelated to phentermine, and we speculate whether this could have reflected autonomic neuropathy secondary to diabetes mellitus. We believe this patient should not have been be taking phentermine, given that it is known to worsen hypertension. As obesity becomes more prevalent it seems likely that more patients on these medications will be encountered by anaesthetists. These drugs may have anaesthetic implications and it seems prudent to recommend ceasing them preoperatively. This requires knowledge of the relevant half-life and we suggest that, preferably, phentermine is ceased seven to ten days preoperatively. In the era of day of surgery admission or in an emergency, this may not be possible, and it seems reasonable to manage such patients using perioperative beta-blockade and/or clonidine, with arterial blood pressure monitoring 8 . Patients may neglect to mention their anti-obesity medication use out of embarrassment or because of a lack of understanding of the anaesthetic relevance, so direct questioning about anti-obesity medication may be advisable.
